0000899243-20-023892.txt : 20200902 0000899243-20-023892.hdr.sgml : 20200902 20200902160519 ACCESSION NUMBER: 0000899243-20-023892 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200901 FILED AS OF DATE: 20200902 DATE AS OF CHANGE: 20200902 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Turtle Cameron CENTRAL INDEX KEY: 0001758363 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38959 FILM NUMBER: 201156991 MAIL ADDRESS: STREET 1: C/O EIDOS THERAPEUTICS, INC. STREET 2: 101 MONTGOMERY STREET, SUITE 2550 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BridgeBio Pharma, Inc. CENTRAL INDEX KEY: 0001743881 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 BUSINESS PHONE: (650) 391-9740 MAIL ADDRESS: STREET 1: 421 KIPLING STREET CITY: PALO ALTO STATE: CA ZIP: 94301 FORMER COMPANY: FORMER CONFORMED NAME: BridgeBio Pharma LLC DATE OF NAME CHANGE: 20180618 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-01 0 0001743881 BridgeBio Pharma, Inc. BBIO 0001758363 Turtle Cameron C/O BRIDGEBIO PHARMA, INC. 421 KIPLING STREET PALO ALTO CA 94301 0 1 0 0 See Remarks Common Stock 2020-09-01 4 A 0 2745 0.00 A 12568 D The shares were acquired in connection with an equity exchange program involving the issuance of equity awards under the Issuer's 2019 Stock Option and Incentive Plan in exchange for existing equity held by the Reporting Person in privately-held subsidiaries of the Issuer. Senior Vice President, Portfolio Management and Corporate Development /s/ Tara Condon, Attorney-in-Fact 2020-09-02